BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lahiff C, Safaie P, Awais A, Akbari M, Gashin L, Sheth S, Lembo A, Leffler D, Moss AC, Cheifetz AS. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2013;37:786-794. [PMID: 23432394 DOI: 10.1111/apt.12262] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 7.4] [Reference Citation Analysis]
Number Citing Articles
1 Tan M. Importance of defining loss of response before therapeutic drug monitoring. Gut 2015;64:516.2-517. [DOI: 10.1136/gutjnl-2014-307877] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Chang J, Leong RW, Wasinger VC, Ip M, Yang M, Phan TG. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing. Gastroenterology 2017; 153: 723-731. e1. [PMID: 28601482 DOI: 10.1053/j.gastro.2017.05.056] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 18.4] [Reference Citation Analysis]
3 Chen F, Hu Y, Fan YH, Lv B. Clinical Value of Fecal Calprotectin in Predicting Mucosal Healing in Patients With Ulcerative Colitis. Front Med (Lausanne) 2021;8:679264. [PMID: 34414201 DOI: 10.3389/fmed.2021.679264] [Reference Citation Analysis]
4 Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 2014;109:1055-64. [PMID: 24796769 DOI: 10.1038/ajg.2014.106] [Cited by in Crossref: 95] [Cited by in F6Publishing: 94] [Article Influence: 11.9] [Reference Citation Analysis]
5 Parra RS, Chebli JM, Amarante HM, Flores C, Parente JM, Ramos O, Fernandes M, Rocha JJ, Feitosa MR, Feres O, Scotton AS, Nones RB, Lima MM, Zaltman C, Goncalves CD, Guimaraes IM, Santana GO, Sassaki LY, Hossne RS, Bafutto M, Junior RL, Faria MA, Miszputen SJ, Gomes TN, Catapani WR, Faria AA, Souza SC, Caratin RF, Senra JT, Ferrari ML. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil. World J Gastroenterol 2019; 25(38): 5862-5882 [PMID: 31636478 DOI: 10.3748/wjg.v25.i38.5862] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
6 Ludvigsson JF, Ciacci C, Green PH, Kaukinen K, Korponay-Szabo IR, Kurppa K, Murray JA, Lundin KEA, Maki MJ, Popp A, Reilly NR, Rodriguez-Herrera A, Sanders DS, Schuppan D, Sleet S, Taavela J, Voorhees K, Walker MM, Leffler DA. Outcome measures in coeliac disease trials: the Tampere recommendations. Gut. 2018;67:1410-1424. [PMID: 29440464 DOI: 10.1136/gutjnl-2017-314853] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 13.3] [Reference Citation Analysis]
7 Pedersen N, Ankersen DV, Felding M, Wachmann H, Végh Z, Molzen L, Burisch J, Andersen JR, Munkholm P. Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(18): 3356-3366 [PMID: 28566897 DOI: 10.3748/wjg.v23.i18.3356] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 62] [Article Influence: 14.6] [Reference Citation Analysis]
8 Kopylov U, Rosenfeld G, Bressler B, Seidman E. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:742-756. [PMID: 24562174 DOI: 10.1097/01.mib.0000442681.85545.31] [Cited by in Crossref: 99] [Cited by in F6Publishing: 37] [Article Influence: 14.1] [Reference Citation Analysis]
9 Stawczyk-Eder K, Eder P, Lykowska-Szuber L, Krela-Kazmierczak I, Klimczak K, Szymczak A, Szachta P, Katulska K, Linke K. Is faecal calprotectin equally useful in all Crohn’s disease locations? A prospective, comparative study. Arch Med Sci. 2015;11:353-361. [PMID: 25995752 DOI: 10.5114/aoms.2014.43672] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
10 Norton C, Czuber-Dochan W, Artom M, Sweeney L, Hart A. Systematic review: interventions for abdominal pain management in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46:115-125. [PMID: 28470846 DOI: 10.1111/apt.14108] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 7.6] [Reference Citation Analysis]
11 Sassaki LY, Miszputen SJ, Kaiser Junior RL, Catapani WR, Bafutto M, Scotton AS, Zaltman C, Baima JP, Ramos HS, Faria MAG, Gonçalves CD, Guimaraes IM, Flores C, Amarante HMBS, Nones RB, Parente JML, Lima MM, Chebli JM, Ferrari MLA, Campos JF, Sanna MGP, Ramos O, Parra RS, da Rocha JJR, Feres O, Feitosa MR, Caratin RF, Senra JT, Santana GO. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil. World J Gastroenterol 2021; 27(23): 3396-3412 [PMID: 34163120 DOI: 10.3748/wjg.v27.i23.3396] [Reference Citation Analysis]
12 Lu Y, Zhou L, Liu L, Feng Y, Lu L, Ren X, Dong X, Sang W. Serum omentin-1 as a disease activity marker for Crohn’s disease. Dis Markers. 2014;2014:162517. [PMID: 24659847 DOI: 10.1155/2014/162517] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
13 Morris MW, Stewart SA, Heisler C, Sandborn WJ, Loftus EV, Zello GA, Fowler SA, Jones JL. Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity. Inflamm Bowel Dis 2018;24:277-85. [PMID: 29361090 DOI: 10.1093/ibd/izx018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
14 Adler J, Eder SJ, Gebremariam A, Moran CJ, Bass LM, Moses J, Lewis JD, Singer AAM, Morhardt TL, Picoraro JA, Cardenas V, Zacur GM, Colletti RB. Quantification of Mucosal Activity from Colonoscopy Reports via the Simplified Endoscopic Mucosal Assessment for Crohn's Disease. Inflamm Bowel Dis 2021:izab315. [PMID: 34964861 DOI: 10.1093/ibd/izab315] [Reference Citation Analysis]
15 van Wassenaer EA, de Voogd FAE, van Rijn RR, van Der Lee JH, Tabbers MM, van Etten-Jamaludin FS, Gecse KB, Kindermann A, De Meij TGJ, D'haens GR, Benninga MA, Koot BGP. Diagnostic Accuracy of Transabdominal Ultrasound in Detecting Intestinal Inflammation in Paediatric IBD Patients-a Systematic Review. J Crohns Colitis 2019;13:1501-9. [PMID: 31329839 DOI: 10.1093/ecco-jcc/jjz085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
16 Khan I, Samson SE, Grover AK. Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal. Med Princ Pract 2017;26:201-17. [PMID: 28278495 DOI: 10.1159/000468988] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
17 Kopylov U, Yablecovitch D, Lahat A, Neuman S, Levhar N, Greener T, Klang E, Rozendorn N, Amitai MM, Ben-Horin S, Eliakim R. Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging. Am J Gastroenterol. 2015;110:1316-1323. [PMID: 26215531 DOI: 10.1038/ajg.2015.221] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 12.3] [Reference Citation Analysis]
18 Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G. Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol 2018;52:e53-62. [PMID: 28723856 DOI: 10.1097/MCG.0000000000000837] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
19 Zhang M, Zhou L, Wang Y, Dorfman RG, Tang D, Xu L, Pan Y, Zhou Q, Li Y, Yin Y, Zhao S, Wu J, Yu C. Faecalibacterium prausnitzii produces butyrate to decrease c-Myc-related metabolism and Th17 differentiation by inhibiting histone deacetylase 3. Int Immunol 2019;31:499-514. [PMID: 30809639 DOI: 10.1093/intimm/dxz022] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
20 Boland BS, Boyle DL, Sandborn WJ, Firestein GS, Levesque BG, Hillman J, Zhang B, Proudfoot J, Eckmann L, Ernst PB, Rivera-Nieves J, Pola S, Copur-Dahi N, Zou G, Chang JT. Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease. Inflamm Bowel Dis 2015;21:323-30. [PMID: 25545378 DOI: 10.1097/MIB.0000000000000264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
21 Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, D'Haens G, Sandborn WJ, Feagan BG, Levesque BG. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther. 2015;42:1200-1210. [PMID: 26388424 DOI: 10.1111/apt.13408] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 8.7] [Reference Citation Analysis]
22 Moss AC. Therapeutic drug monitoring, mucosal healing, deep remission: the path to nirvana in Crohn's disease? Clin Gastroenterol Hepatol 2014;12:432-3. [PMID: 24370555 DOI: 10.1016/j.cgh.2013.12.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
23 Halloran BP, Jamil LH, Lo SK, Reeson M, Vasiliauskas EA, Targan S, Ippoliti A, Mann NK, Melmed GY. Double-Balloon Endoscopy in Crohn Disease: A Tertiary Referral Center Experience. Inflamm Bowel Dis 2021;27:1248-55. [PMID: 33155643 DOI: 10.1093/ibd/izaa287] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Ma C, Battat R, Khanna R, Parker CE, Feagan BG, Jairath V. What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity? Best Pract Res Clin Gastroenterol 2019;38-39:101602. [PMID: 31327404 DOI: 10.1016/j.bpg.2019.02.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
25 Li B, Wu Y, Wang Z, Xing M, Xu W, Zhu Y, Du P, Wang X, Yang H. Non-invasive diagnosis of Crohn's disease based on SERS combined with PCA-SVM. Anal Methods 2021;13:5264-73. [PMID: 34665186 DOI: 10.1039/d1ay01377g] [Reference Citation Analysis]
26 Zargar A, Gooraji SA, Keshavarzi B, Haji Aghamohammadi AA. Effect of Irritable Bowel Syndrome on Sleep Quality and Quality of Life of Inflammatory Bowel Disease in Clinical Remission. Int J Prev Med 2019;10:10. [PMID: 30774844 DOI: 10.4103/ijpvm.IJPVM_364_17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
27 Levesque BG, Greenberg GR, Zou G, Sandborn WJ, Singh S, Hauenstein S, Ohrmund L, Wong CJ, Stitt LW, Shackelton LM, King D, Lockton S, Ducharme J, Feagan BG. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther 2014;39:1126-35. [PMID: 24689499 DOI: 10.1111/apt.12733] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 9.9] [Reference Citation Analysis]
28 Park KT, Crandall WV, Fridge J, Leibowitz IH, Tsou M, Dykes DM, Hoffenberg EJ, Kappelman MD, Colletti RB. Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease. Inflamm Bowel Dis 2014;20:946-51. [PMID: 24451222 DOI: 10.1097/01.MIB.0000441349.40193.aa] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
29 Khanna R, Zou G, D'Haens G, Rutgeerts P, McDonald JW, Daperno M, Feagan BG, Sandborn WJ, Dubcenco E, Stitt L, Vandervoort MK, Donner A, Luo A, Levesque BG. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut 2016;65:1119-25. [PMID: 25935574 DOI: 10.1136/gutjnl-2014-308973] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
30 Cheng FK, McLean LP, Cross RK. What is the role of vedolizumab in the era of anti-TNF agents? Ann Transl Med 2014;2:4. [PMID: 25332980 DOI: 10.3978/j.issn.2305-5839.2013.10.01] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Novak K, Tanyingoh D, Petersen F, Kucharzik T, Panaccione R, Ghosh S, Kaplan GG, Wilson A, Kannengiesser K, Maaser C. Clinic-based Point of Care Transabdominal Ultrasound for Monitoring Crohn's Disease: Impact on Clinical Decision Making. J Crohns Colitis. 2015;9:795-801. [PMID: 26079723 DOI: 10.1093/ecco-jcc/jjv105] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
32 Wynne J, Kozuch P. Medical marijuana for inflammatory bowel disease: the highs and lows. Scand J Gastroenterol 2021;:1-9. [PMID: 34919496 DOI: 10.1080/00365521.2021.1998604] [Reference Citation Analysis]
33 Berrill JW, Sadlier M, Hood K, Green JT. Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. J Crohns Colitis. 2014;8:945-955. [PMID: 24529603 DOI: 10.1016/j.crohns.2014.01.018] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 7.4] [Reference Citation Analysis]
34 Ma X, Li Y, Jia H, Zhang J, Wang G, Liu X, Song Y. Contrast-enhanced ultrasound in the diagnosis of patients suspected of having active Crohn's disease: meta-analysis. Ultrasound Med Biol. 2015;41:659-668. [PMID: 25619783 DOI: 10.1016/j.ultrasmedbio.2014.09.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
35 Khanna R, Zou G, Feagan BG. Evolution of the Randomized Controlled Trial in Inflammatory Bowel Disease: Current Challenges and Future Solutions. Inflamm Bowel Dis 2018;24:2155-64. [PMID: 29788218 DOI: 10.1093/ibd/izy117] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015; 148:37-51.e1. [PMID: 25127678 DOI: 10.1053/j.gastro.2014.08.003] [Cited by in Crossref: 142] [Cited by in F6Publishing: 124] [Article Influence: 17.8] [Reference Citation Analysis]
37 Fu Y, Wang L, Xie C, Zou K, Tu L, Yan W, Hou X. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation. Sci Rep. 2017;7:2669. [PMID: 28572616 DOI: 10.1038/s41598-017-02835-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
38 Moore C, Corbett G, Moss AC. Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10:619-625. [PMID: 26763722 DOI: 10.1093/ecco-jcc/jjw007] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 10.5] [Reference Citation Analysis]
39 Kuai XY, Yu SY, Cui XF, Zhao XJ, Mao XQ, Yu Y, Hu T, Zhang HJ, Zhou CL. LncRNA LUCAT1 as a Plasma Biomarker for Assessing Disease Activity in Adult Patients with Crohn's Disease. Gastroenterol Res Pract 2021;2021:5557357. [PMID: 34621310 DOI: 10.1155/2021/5557357] [Reference Citation Analysis]
40 Mohamadi J, Ghazanfari F, Drikvand FM. Comparison of the Effect of Dialectical Behavior Therapy, Mindfulness Based Cognitive Therapy and Positive Psychotherapy on Perceived Stress and Quality of Life in Patients with Irritable Bowel Syndrome: a Pilot Randomized Controlled Trial. Psychiatr Q 2019;90:565-78. [DOI: 10.1007/s11126-019-09643-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
41 Berrill JW, Green JT, Hood K, Campbell AK. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther. 2013;38:44-51. [PMID: 23668698 DOI: 10.1111/apt.12335] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 7.0] [Reference Citation Analysis]
42 Rispo A, Imperatore N, Testa A, Bucci L, Luglio G, De Palma GD, Rea M, Nardone OM, Caporaso N, Castiglione F. Combined Endoscopic/Sonographic-based Risk Matrix Model for Predicting One-year Risk of Surgery: A Prospective Observational Study of a Tertiary Centre Severe/Refractory Crohn's Disease Cohort. J Crohns Colitis. 2018;12:784-793. [PMID: 29528382 DOI: 10.1093/ecco-jcc/jjy032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
43 Bassotti G, Antonelli E, Villanacci V, Nascimbeni R, Dore MP, Pes GM, Maconi G. Abnormal gut motility in inflammatory bowel disease: an update. Tech Coloproctol 2020;24:275-82. [PMID: 32062797 DOI: 10.1007/s10151-020-02168-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
44 Vaughn BP, Shah S, Cheifetz AS. The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol 2014;12:103-17. [PMID: 24395615 DOI: 10.1007/s11938-013-0008-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
45 Boland BS, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43:603-617. [PMID: 25110261 DOI: 10.1016/j.gtc.2014.05.011] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
46 Weimers P, Burisch J. The Importance of Detecting Irritable Bowel-like Symptoms in Inflammatory Bowel Disease Patients. Journal of Crohn's and Colitis 2018;12:385-6. [DOI: 10.1093/ecco-jcc/jjy012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Ghosh S, Sandborn WJ, Colombel JF, Feagan BG, Panaccione R, Hanauer S, Schreiber S, Peyrin-Biroulet L, Vermeire S, Eichner S, Huang B, Robinson AM, Pappalardo B. Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. Inflamm Bowel Dis 2016;22:2711-23. [PMID: 27585411 DOI: 10.1097/MIB.0000000000000909] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
48 Teruel C, Garrido E, Mesonero F. Diagnosis and management of functional symptoms in inflammatory bowel disease in remission. World J Gastrointest Pharmacol Ther 2016; 7(1): 78-90 [PMID: 26855814 DOI: 10.4292/wjgpt.v7.i1.78] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
49 Steenholdt C, Ainsworth MA. Authors' response: Importance of defining loss of response before therapeutic drug monitoring. Gut 2015;64:1340-1. [PMID: 25588404 DOI: 10.1136/gutjnl-2014-309044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
50 Novak KL, Jacob D, Kaplan GG, Boyce E, Ghosh S, Ma I, Lu C, Wilson S, Panaccione R. Point of Care Ultrasound Accurately Distinguishes Inflammatory from Noninflammatory Disease in Patients Presenting with Abdominal Pain and Diarrhea. Can J Gastroenterol Hepatol. 2016;2016:4023065. [PMID: 27446838 DOI: 10.1155/2016/4023065] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
51 Crandall W. T3 translational science in gastroenterology: getting to best outcomes. Clin Gastroenterol Hepatol 2013;11:1559-61. [PMID: 24107397 DOI: 10.1016/j.cgh.2013.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
52 Moss AC. Editorial: adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease. Aliment Pharmacol Ther 2014;40:1249-1249. [DOI: 10.1111/apt.12966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 Giri S, A S, Jearth V. Deep Remission in Crohn's Disease: Optional or Quintessential. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01355-0. [PMID: 34968727 DOI: 10.1016/j.cgh.2021.12.031] [Reference Citation Analysis]
54 Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43:1069-1079. [PMID: 26953251 DOI: 10.1111/apt.13585] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
55 Serafin Z, Białecki M, Białecka A, Sconfienza LM, Kłopocka M. Contrast-enhanced Ultrasound for Detection of Crohn's Disease Activity: Systematic Review and Meta-analysis. J Crohns Colitis 2016;10:354-62. [PMID: 26507861 DOI: 10.1093/ecco-jcc/jjv196] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
56 Khanna R, Jairath V, Feagan BG. The Evolution of Treatment Paradigms in Crohn's Disease: Beyond Better Drugs. Gastroenterol Clin North Am 2017;46:661-77. [PMID: 28838421 DOI: 10.1016/j.gtc.2017.05.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
57 Auer K, Trachter R, Van den Bogaerde J, Bassaganya-Riera J, Sorrentino D. Translational research and efficacy of biologics in Crohn’s disease: a cautionary tale. Expert Rev Clin Immunol. 2014;10:219-229. [PMID: 24410538 DOI: 10.1586/1744666x.2014.877839] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease. J Crohns Colitis 2015;9:238-45. [PMID: 25576753 DOI: 10.1093/ecco-jcc/jjv004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
59 Campbell JP, Zierold C, Rode AM, Blocki FA, Vaughn BP. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome. J Clin Gastroenterol 2021;55:239-43. [PMID: 32324678 DOI: 10.1097/MCG.0000000000001359] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
60 Khanna R, Zou G, D'Haens G, Feagan BG, Sandborn WJ, Vandervoort MK, Rolleri RL, Bortey E, Paterson C, Forbes WP, Levesque BG. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. Aliment Pharmacol Ther 2015;41:77-86. [PMID: 25348809 DOI: 10.1111/apt.13001] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 10.8] [Reference Citation Analysis]
61 Cheifetz AS. Management of active Crohn disease. JAMA 2013;309:2150-8. [PMID: 23695484 DOI: 10.1001/jama.2013.4466] [Cited by in Crossref: 72] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
62 Khanna R, Levesque BG, Sandborn WJ. Measuring what counts—endoscopic assessment in IBD. Nat Rev Gastroenterol Hepatol 2014;11:9-10. [DOI: 10.1038/nrgastro.2013.233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
63 Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvenstein M, Rimola J, Panes J, D’haens G, Sandborn WJ, Feagan BG. Evolving Concepts in Phases I and II Drug Development for Crohn’s Disease. ECCOJC 2017;11:246-55. [DOI: 10.1093/ecco-jcc/jjw137] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
64 Ogasawara H, Hayasaka M, Maemoto A, Furukawa S, Ito T, Kimura O, Endo T. Stable isotope ratios of carbon, nitrogen and selenium concentration in the scalp hair of Crohn's disease patients who ingested the elemental diet Elental®. Rapid Commun Mass Spectrom 2019;33:41-8. [PMID: 30280438 DOI: 10.1002/rcm.8296] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
65 Al-Bawardy B. Inflammatory bowel disease: Clinical screening and transition of care. Saudi J Gastroenterol 2017;23:213-5. [PMID: 28721973 DOI: 10.4103/sjg.SJG_294_17] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
66 Chen WC, Quigley EM. Commentary: irritable bowel syndrome and the CDAI--misleading activity by straw men. Aliment Pharmacol Ther. 2013;37:1020-1021. [PMID: 23590538 DOI: 10.1111/apt.12287] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
67 Kurada S, Alkhouri N, Fiocchi C, Dweik R, Rieder F. Review article: breath analysis in inflammatory bowel diseases. Aliment Pharmacol Ther 2015;41:329-41. [PMID: 25523187 DOI: 10.1111/apt.13050] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
68 Ma C, Battat R, Parker CE, Khanna R, Jairath V, Feagan BG. Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease? Expert Review of Gastroenterology & Hepatology 2019;13:319-30. [DOI: 10.1080/17474124.2019.1563481] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
69 Bassotti G, Antonelli E, Villanacci V, Salemme M, Coppola M, Annese V. Gastrointestinal motility disorders in inflammatory bowel diseases. World J Gastroenterol 2014; 20(1): 37-44 [PMID: 24415856 DOI: 10.3748/wjg.v20.i1.37] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]